,6,7,8 Depleting both monocyte-derived and lung-resident TAMs enhanced tumor response to “antiangiogenic immunotherapy” (a combination of VEGFA, angiopoietin-2, and PD1 blockade) in NSCLC models.13 This evidence concerns the gene VEGFA and non-small cell lung carcinoma.